Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Regeneron Pharmaceuticals



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Regeneron Pharmaceuticals rose $17.27 (6.2%) to $293.68 on average volume. Throughout the day, 1,105,944 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 786,100 shares. The stock ranged in a price between $280.63-$294.78 after having opened the day at $286.00 as compared to the previous trading day's close of $276.41. Other companies within the Health Care sector that increased today were:

Ariad Pharmaceuticals



), up 35.5%,

Galena Biopharma



), up 14.6%,




TheStreet Recommends

), up 14.6% and

Cardiome Pharma Corporation



), up 14.4%.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $26.8 billion and is part of the drugs industry. The company has a P/E ratio of 38.4, above the S&P 500 P/E ratio of 17.7. Shares are up 61.6% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share.

On the negative front,

Mast Therapeutics



), down 38.6%,

CombiMatrix Corporation



), down 14.1%,

Conatus Pharmaceuticals



), down 11.9% and

Amarin Corporation



), down 11.5% , were all laggards within the health care sector with

Rockwell Medical



) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.